IRCCS Azienda Ospedaliero - Universitaria di Bologna
Bologna, 40138, Italy
Location status: Recruiting
Location contact
Alessandro Broccoli, MD
CONTACT
Pier Luigi Zinzani, MD
CONTACT
Pier Luigi Zinzani, MD
CONTACT
NCT Number: NCT06781437
observational, non-interventional, retrospective, single-center study focusing on patients with lymphoma / lymphoproliferative syndrome between January 1980 and September 2021
Interested in participating?
Request Info18 year and older
All sexes
Observational
Bologna, 40138, Italy
Location status: Recruiting
Alessandro Broccoli, MD
CONTACT
Pier Luigi Zinzani, MD
CONTACT
Pier Luigi Zinzani, MD
CONTACT
observational, non-interventional, retrospective, single-center study focusing on patients with lymphoma / lymphoproliferative syndrome between January 1980 and September 2021.
Study objectives are to enrich the data on the prognostic role of clinical and epidemiological factors associated with clinical and epidemiological data of patients;
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Time frame: through study completion, an average of 6 years
Incidence and prevalence
Time frame: through study completion, an average of 6 years
Overall Survival (OS)
Time frame: through study completion, an average of 6 years
event free survival (EFS)
Time frame: through study completion, an average of 6 years
Lymphoma specific survival (LSS)
Time frame: through study completion, an average of 6 years
Progression Free Survival (PFS)
Time frame: through study completion, an average of 6 years
Net survival
Time frame: through study completion, an average of 6 years
Response rate
Time frame: through study completion, an average of 6 years
Duration of Response (DoR)
Time frame: through study completion, an average of 6 years
time to next anti-lymphoma treatment (TTNLT)
Time frame: through study completion, an average of 6 years
Duration of survival after progression
Time frame: through study completion, an average of 6 years
lymphoma transformation frequency
Time frame: through study completion, an average of 6 years
Frequency of secondary neoplasy
Time frame: through study completion, an average of 6 years
frequency of other chronic diseases
Contact information is provided by the study sponsor or research team.
Alessandro Broccoli, MD
CONTACT
Pier Luigi Zinzani, MD
CONTACT
IRCCS Azienda Ospedaliero-Universitaria di Bologna
Other
Studio Osservazionale Retrospettivo Di Coorte Italiana Di Pazienti Con Linfoma (RETRO-LYMPH)
Acronym: RETRO-LYMPH
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT06218602
Hemic and Lymphatic Diseases, Immune System Diseases
Houston, Texas, United States
View Trial DetailsNCT01441089
Adnexal Diseases, Breast Cancer
Bethesda, Maryland, United States
View Trial DetailsNCT03258567
DNA Virus Infections, Disorders, Lymphoproliferative
Bethesda, Maryland, United States
View Trial DetailsNCT03223610
Burkitt Lymphoma, DNA Virus Infections
Bethesda, Maryland, United States
View Trial Details